India, Oct. 19 -- Veradermics, Incorporated (MANE) is up 6.98 percent, gaining $7.60 to $116.42 on Monday. The rise follows positive topline results from Part A of the company's Phase 3 Study '304' evaluating VDPHL01, its extended-release oral minoxidil formulation, in 536 males with mild-to-moderate pattern hair loss. The trial met all primary and secondary endpoints with high statistical significance.
Veradermics is currently trading at $116.42, up from the previous close of $108.82 after opening at $115.34 on the New York Stock Exchange. The stock has traded between $113.55 and $119.38 during the session. Trading volume stands at about 577,000 shares, compared with average volume of about 775,000 shares.
googletag.cmd.push(function() {...